Clinical trials: NMDAR Autoimmune Encephalitis, open to volunteers
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Autoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR…
- Trial name
- RADIA (NCT06867991)
- Testing
- Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- The First People's Hospital of Changzhou
Encephalitis, Encephalitis, Viral
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)
Based on the records of traditional Chinese medicine, CBS has the functions of purifying the heart, eliminating phlegm, stimulating bile secretion, and soothing the nerves.
- Conditions
- Encephalitis, Encephalitis, Viral, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis
- Trial name
- NCT06584045
- Testing
- Calculus bovis sativus (CBS)
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Autoimmune Encephalitis
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before…
- Trial name
- ENCEPHATAIP (NCT06079294)
- Testing
- FDG PET
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NMDAR Autoimmune Encephalitis
Long-term Impact of NMDAR Encephalitis, Level 3
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year.
- Trial name
- SAPIENCE 3 (NCT07158229)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Encephalitis
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily substances, called antibodies. Antibodies normally help the body to prevent infections.
- Trial name
- Generate-Boost (NCT03993262)
- Testing
- Bortezomib
- Where
- 17 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Jena University Hospital
Autoimmune Encephalitis, Anti-NMDAR Encephalitis
Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies
This multicenter, blinded, cross-sectional study aims to evaluate the clinical performance of a novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABAB receptor (anti-GABABR) antibodies.
- Conditions
- Autoimmune Encephalitis, Anti-NMDAR Encephalitis, Anti-GABABR Encephalitis
- Trial name
- GREAT (NCT07858175)
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis
Medium-term Effects of Treatments in Autoimmune Encephalitis
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence.
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis, CASPR2-Antibody, IgLON5
- Trial name
- META (NCT07133113)
- Testing
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis.
- Trial name
- NCT06510283
- Testing
- Taitacept
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tongren Hospital
Autoimmune Encephalitis, Encephalitis
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and…
- Trial name
- ExTINGUISH (NCT04372615)
- Testing
- Inebilizumab
- Where
- 39 sites in United States, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- University of Utah
Optic Neuritis, Transverse Myelitis
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland.
- Conditions
- Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- NCT05017142
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
This study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or…
- Conditions
- Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease, Autoimmune Encephalitis
- Trial name
- NCT07093333
- Testing
- ART5803, ART5803-Cohort D
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Arialys Australia Pty Ltd
Neuropsychiatric Symptom
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment…
- Trial name
- DIAMOND (NCT07791212)
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- King's College London
Encephalitis Autoimmune
Efgartigimod in Anti-NMDA Receptor Encephalitis.
This study is a multicenter, open-label, single-arm exploratory trial designed to enroll 20 eligible patients with anti-NMDAR encephalitis.
- Trial name
- ANSWER (NCT07822776)
- Testing
- Efgartigimod Alfa
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital